Evidence for Enhanced Oxidative Stress in Coronary Heart Disease and Chronic Heart Failure

  • Roswitha Wolfram
  • Anthony Oguogho
  • Barbara Palumbo
  • Helmut Sinzinger
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 525)


Oxidation injury has been claimed as one of the key factors in the development of coronary heart disease and chronic heart failure [1,2]. The isoprostane 8-epi-PGF2 is gaining increasing interest as reliable marker of in-vivo oxidation injury [3]. As it causes among others coronary vasoconstriction [4] its pathophysiological role may become even more important. We therefore assessed the isoprostane 8-epi-PGF in arteries, veins, heart valves and myocardial tissue immunochemically as well as by immunohistochemistry. Furthermore, 8-epi-PGF was determined in plasma and urine of patients with CHD compared to patients with dilated and ischemic CMP.


Coronary Heart Disease Chronic Heart Failure Heart Valve Silicic Acid Coronary Vasoconstriction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cracowski JL, Tremel F, Marpeau C, et al. Increased formation of F2-isoprostanes in patients with severe heart failure. Heart 2000; 84: 439–440.PubMedCrossRefGoogle Scholar
  2. 2.
    McMurray J, Chopra M, Abdullah I. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14: 1493–1498.PubMedCrossRefGoogle Scholar
  3. 3.
    Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997; 36: 1–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Kromer BM, Tippins JR. Coronary artery constriction by the isoprostane 8-epi-PGF. Brit J Pharmacol 1996; 119: 1276–1280.CrossRefGoogle Scholar
  5. 5.
    Mehrabi MR, Ekmekcioglu C, Tatzber F, Oguogho A, Ullrich R, Morgan A, Tamaddon R, Grimm M, Glogar HD, Sinzinger H. The isoprosatne, 8-epi-PGF, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc Res 1999; 43:492–499.PubMedCrossRefGoogle Scholar
  6. 6.
    Mehrabi MR, Serbecic N, Ekmekcioglu C, Tamaddon F, Ullrich R, Sinzinger H, Glogar HD. The isoprostane 8-epi-PGF is a valuable indicator of oxidative injury in human heart valves. Cardiovasc Pathol 2001; 10: 241–245.PubMedCrossRefGoogle Scholar
  7. 7.
    Wolfram R, Oguogho A, Palumbo B, Sinzinger H. Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by increased 8-epi-PGF. J Am Coll Cardiol 2003 (submitted).Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Roswitha Wolfram
    • 1
  • Anthony Oguogho
    • 2
  • Barbara Palumbo
    • 3
  • Helmut Sinzinger
    • 4
  1. 1.Department of AngiologyUniversity of ViennaViennaAustria
  2. 2.Department of Nuclear MedicineUniversity of ViennaViennaAustria
  3. 3.Department of Nuclear MedicineUniversitá degli Studi, Policlinio MontelucePerugiaItaly
  4. 4.Wilhelm Auerswald Atherosclerosis Research GroupViennaAustria

Personalised recommendations